AGM Information • Mar 18, 2016
AGM Information
Open in ViewerOpens in native device viewer
The Extraordinary General Meeting of BioGaia AB (publ) on 18 March 2016 resolved on:
Peter Rothschild, Group President, BioGaia: +46 8 555 293 00
2016-03-12 Meta-analysis confirms effectiveness of BioGaia ProDentis in periodontitis 2016-03-12 Notice to attend the Extraordinary General Meeting of BioGaia AB (publ) 2016-02-12 Proposal for distribution and separate listing of BioGaia's subsidiary Infant Bacterial Therapeutics
BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 18 March 2016, 4.00 p.m. CET.
BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.